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Abstract
E6 oncoproteins from human papillomavirus type 16 (16E6) and Bovine Papillomavirus type 1 (BE6) bind to leucine rich peptides
(called charged leucine, LXXLL, or signature peptides) found on target cellular proteins. BE6 and 16E6 both bind the product of the UBE3A
gene called E6AP on a charged leucine peptide, LQELL. E6AP is an E3 ubiquitin ligase that together with 16E6 interacts with p53 to target
p53 degradation. Although both BE6 and 16E6 bind the LQELL peptide of E6AP, only 16E6 acts as an adapter to then bring p53 to E6AP.
In order to determine how E6 proteins function as adapters, 16E6, p53, and E6AP were expressed in yeast, and were shown to form a
tri-molecular complex. 16E6 mutants were selected that retained interactions with E6AP yet were defective for interaction with p53. Such
16E6 mutations were typically within the amino-terminus of 16E6. Through the use of E6AP null cells, transfected E6AP was shown to
be necessary and sufficient for the degradation of p53 in the presence of 16E6. However, the interaction of 16E6 with E6AP was complex.
While BE6 interacts only with the LQELL motif of E6AP, an intact LQELL motif is not necessary either for interaction of 16E6 with E6AP
or for p53 degradation. In addition, 16E6 mutants that fail to bind the LQELL motif of E6AP can support p53 degradation. These results
indicate that 16E6 may have multiple modes of interaction with E6AP and that assembly of p53 containing complexes for targeted
degradation by E6AP may occur in more than one way. These results have implications for potential targeting of the interaction of 16E6
and E6AP in the therapy of HPV-induced cancer.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Papillomaviruses are causative agents for a variety of
benign and malignant epithelial tumors. Epithelial transfor-
mation by papillomaviruses is induced by the expression of
virus-encoded oncogenes E5, E6, and E7. In HPV types that
are associated with malignancy, E6 proteins degrade p53,
and E7 proteins degrade the retinoblastoma protein, among
other cellular targets (recently reviewed in Munger (2002)
and Mantovani and Banks (2001).
Papillomavirus E6 oncogenes are small zinc-binding
proteins with conserved structure but diverse activities. The
cancer-associated E6 oncoprotein from HPV-16 (16E6) in-
teracts with a cellular protein termed E6AP and together
with E6AP binds to the p53 tumor suppressor protein
(Huibregtse et al., 1991). E6AP, the product of the UBE3A
gene, is the prototype member of the HECT domain E3
ubiquitin ligase family (Huibregtse et al., 1995). Formation
of the E6-E6AP-p53 complex leads to the degradation of
p53 through ubiquitin-mediated proteolysis that requires the
E3 ubiquitin ligase activity of E6AP (Huibregtse et al.,
1993a). E6 functions as an adapter protein in the complex
with p53, as E6AP does not interact with p53 in the absence
of E6 and the degradation of p53 requires both E6 and
E6AP (Huibregtse et al., 1993b). E6 proteins from HPV
types 1, 6, 8, or 11 do not target p53 for degradation (Elbel
et al., 1997; Scheffner et al., 1990; Werness et al., 1990),
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and while E6 from Bovine Papillomavirus Type 1 (BE6)
can bind to the same site on E6AP as 16E6, it has not been
reported to degrade p53 (Ned et al., 1997).
The E6 proteins of HPV-16 (16E6) and BE6 bind to the
cellular targets E6AP, ERC-55, and paxillin through inter-
action with homologous peptide sequences found on the
target proteins, variously called charged leucine motifs,
LXXLL motifs, or signature motifs (Chen et al., 1998;
Elston et al., 1998; Vande Pol et al., 1998). In the case of
BE6, transformation of murine C127 cells can be repressed
by competitive charged leucine peptide binding in vivo
(Bohl et al., 2000), demonstrating the importance of this
interaction in transformation. Deletion of a 20 amino acid
segment encompassing the E6AP charged leucine motif
prevents both interaction of E6AP with 16E6 and in vitro
degradation of p53 (Huibregtse et al., 1993b). Mutation of
E6AP cysteine 842 to alanine (termed E6AP_Ub) pre-
vents the formation of an ubiquitin thioester on E6AP,
destroys E6AP ubiquitin transferase activity and prevents
the degradation of p53 (Scheffner et al., 1995). The
E6AP_Ub mutant can act as a dominant negative repres-
sor of E6 dependent p53 degradation, can interact with both
p53 and 16E6, but does not alter p53 levels in the absence
of E6, indicating that E6AP may not directly regulate p53
degradation in the absence of E6 (Talis et al., 1998). E6AP
is sufficient for the degradation of p53 in concert with E6,
as wheat germ lysate that cannot support the degradation of
p53 by in vitro translated E6 becomes competent when
supplemented with E6AP. While this demonstrates the suf-
ficiency of E6AP in this system, the requirement for E6AP
in mammalian cells has not yet been demonstrated. Anti-
sense oligonucleotides to E6AP result in the augmentation
of p53 levels in cervical cancer cell lines, consistent with a
requirement for E6AP and E6 in p53 dependent degradation
(Beer-Romero et al., 1997).
In cells not expressing E6, p53 is degraded by the ubiq-
uitin ligase Mdm2 (Honda et al., 1997). Phosphorylation of
p53 or repression of mdm2 by the mdm2 inhibitor p19arf
results in the stabilization and accumulation of p53. How-
ever, in HPV-positive cancer cells the Mdm2 pathway is
inactive, and p53 degradation requires E6 (Hengstermann et
al., 2001).
Recently, HPV-16 E7 has been shown to rapidly induce
centriole duplication, thereby contributing to aneuploidy
(Munger, 2002). Since p53 null breast epithelia develop
aneuploid cancers at high frequency (Jerry et al., 2000), and
aneuploidy is common in malignant cells that have lost p53
function, E6 could contribute to the malignant progression
of cervical HPV infections. In addition to degrading p53,
bacterially expressed E6 oncoproteins of both high and low
cancer risk types can interact with the carboxyl-terminus of
p53 in vitro (Li and Coffino, 1996), but a clear role for this
interaction in vivo remains to be established. HPV-16 E6
can interact in vitro with the transcriptional co-activators
p300/CBP (Patel et al., 1999; Zimmermann et al., 1999);
such interactions have been proposed to interfere with p53
transactivation. Finally, E6 may alter the intracellular local-
ization of p53, interfering with both p53 degradation and
transcriptional regulation (Freedman and Levine, 1998).
In this study we have used a yeast expression system and
E6AP null mammalian cells to analyze the requirements for
the assembly of a complex of p53, E6AP, and E6. This
system was further used to isolate E6 mutants selective for
loss of interaction with p53, and determine the role of strong
in vitro interaction of E6 with E6AP in the degradation of
p53.
Results
Both BPV-1 E6 (BE6) and HPV-16 E6 (16E6) interact
with E6AP through binding to a leucine rich peptide
(termed LQELL at amino acids 408–415) (Be et al., 2001;
Elston et al., 1998; Vande Pol et al., 1998). Since in vitro
binding assays showed an 18 amino acid peptide encom-
passing this sequence to be the sole site of interaction
between 16E6 and E6AP, binding of 16E6 to this site has
been implicated in the degradation of both p53 and E6AP by
16E6 (Huibregtse et al., 1993b; Kao et al., 2000). While
BE6 can interact with E6AP in yeast and in vitro (Ned et al.,
1997), at the same LQELL site as 16E6, the effect of BE6
expression upon E6AP expression levels have not been
determined. To determine if BE6 expression resulted in a
loss of E6AP, BE6, 16E6, p53 and E6AP were co-expressed
as shown in Fig. 1. While 16E6 expression resulted in the
loss of both p53 and E6AP, BE6 expression did not reduce
the levels of either E6AP or p53 (Fig. 1). The lower expres-
sion of BE6 compared to 16E6 in Fig. 1 was not responsible
for the observed difference in the ability of BE6 to induce
E6AP degradation as additional experiments in which BE6
expression was titrated to be greater than 16E6 showed
similar results as observed in Fig. 1.
Fig. 1. Overexpression of BPV-1 E6 fails to reduce the expression of E6AP
or p53. EE-epitope tagged E6AP and E6 molecules were co-expressed by
vaccinia pTM1 transfection in CV-1 cells as indicated at the bottom of the
figure with human native p53. E6AP and E6 were detected by western blot
with EE-specific monoclonal antibody, and p53 by p53 monoclonal anti-
body Ab8. Expression of 16E6 but not BE6 reduces expression of E6AP
and p53.
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Sequences at the amino-terminus of 16E6 are required
for p53 degradation (Kao et al., 2000). In order to determine
the extent of amino terminal sequences required for inter-
action of 16E6 with E6AP and the degradation of p53 and
E6AP by 16E6, we tested amino-terminal deletion mutants
of 16E6 for in vitro association with bacterially expressed
E6AP. In Fig. 2A the in vitro translated epitope-tagged E6
molecules are seen as doublet bands due to translation from
a methionine at the beginning of the epitope tag and from a
methionine at the beginning of the 16E6 sequence. Fig 2A
shows strong interaction of both bands of HPV-18 E6
(18E6), 16E6, and 16E6 deleted of amino acids 1–8
(16E61–8) with GST-E6AP. Further deletion of 16E6 to
amino acid 13 or beyond caused a great decrease in E6AP-
bound 16E6, with a small residual amount of bound E6,
similar to the level of bound HPV-11 E6, an HPV type not
thought to associate with E6AP. The same set of 16E6
deletion mutants were tested for the ability to decrease
E6AP and p53 expression when co-expressed in a vaccinia
virus expression system. Fig. 2B shows that expression of
16E6 deleted to amino acid 22 still retained the ability to
decrease the expression of E6AP. This is despite the low
level of in vitro interaction of E6AP with 16E6 mutants
deleted beyond amino acid 8 in Fig 2A. Further deletion
beyond the first zinc-finger eliminated the reduction of
E6AP expression as did disruptive mutation within any of
the zinc binding motifs of E6 (data not shown). Surpris-
ingly, p53 expression was decreased by both full length and
16E61–8, while 16E61–13 failed to decrease p53 ex-
pression levels (Fig. 2B). These results indicated that strong
in vitro interactions between 16E6 and E6AP through the
LQELL motif as shown in Fig. 2A might not reflect the
ability of 16E6 mutants to degrade E6AP in vivo. In exper-
iments not shown here, all the 16E6 deletion mutants shown
in Fig 2B fail to degrade p53 in vitro using rabbit reticulo-
cyte translated proteins.
In order to dissect the interactions between 16E6, E6AP,
and p53, the three proteins were expressed in yeast so as to
detect a tri-molecular complex, or trihybrid. Expression of
16E6, E6AP, and p53 has been previously shown to block
p53 transcriptional activation in yeast (Waddell and Jen-
kins, 1998), although the fate of p53 protein expression in
yeast was undetermined. A fusion protein of 16E6 with the
DNA binding domain of lexA was expressed in a yeast
strain containing an integrated lexA responsive lacZ re-
porter (Fig. 3A). The lexA-16E6 fusion weakly activates the
lacZ reporter, and this activation is diminished with co-
expression of unfused E6AP containing a point mutation in
the ubiquitin ligase site, termed E6AP_Ub (for E6AP,
ubiquitin-minus). The Ub mutation was introduced to
abolish the ubiquitin ligase activity of E6AP, and prevent
E6AP dependent degradation. However, further introduc-
tion of p53 into yeast expressing lexA-16E6 and E6AP
resulted in pronounced transactivation of the lexA respon-
sive lacZ reporter (Fig 3A). In the absence of E6AP_Ub,
a very slight activation of the lacZ reporter by p53 was
observed. The three component requirement for lacZ acti-
vation is termed a trihybrid. Trihybrid activation of the lexA
responsive lacZ reporter was observed only with normal
p53 and was not observed with the cancer-derived p53
V143A mutant (data not shown). For as yet unknown rea-
sons, color development was more intense on plates with
galactose as a carbon source instead of glucose.
The expression of E6AP, lexA, lexA fusions, and p53 in
yeast was examined by western blot analysis of whole cell
extracts. Yeast strains expressing either lexA, lexA-16E6,
or native 16E6 were mated to strains expressing the proteins
indicated at the bottom of Fig 3B. In yeast strains expressing
lexA, either wild type E6AP or E6AP_UB was detected,
while in strains expressing either lexA-16E6 or native 16E6
only E6AP_UB could be detected. LexA and LexA-16E6
were detected by antibodies to lexA, but adequate antibod-
ies to 16E6 are not available to detect its expression in yeast.
The expression of native 16E6 can be inferred by the loss of
E6AP expression in cells expressing both genes. Surpris-
Fig. 2. Analysis of the role of amino-terminal sequences in the binding and
degradation of p53 and E6AP. (A) In vitro binding of amino-terminal
truncation mutants of 16E6 with E6AP in vitro. EE-epitope tagged HPV-11
E6 (11E6), HPV-18 E6 (18E6), 16E6 and the indicated amino terminal
truncation mutants of 16E6 were expressed in vitro and tested for interac-
tion with bacterially expressed GST-E6AP immobilized on beads. (B) Wild
type and the indicated amino-terminal deletion mutants of EE-epitope
tagged 16E6 were overexpressed together with epitope tagged E6AP and
human p53 by the vaccinia pTM1 system. Vector refers to empty pTM1
vector without 16E6.
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ingly, p53 protein levels were unaltered by co-expression of
E6AP, 16E6, or the combination of E6 and E6AP.
Because transactivation of a lexA responsive reporter
required all three components of the trihybrid (lexA-16E6,
p53, and E6AP_UB), this suggested trihybrid transac-
tivation could be used to dissect the interaction of the
three components of the trihybrid. A library of 16E6 mu-
tants fused to lexA was expressed in a lexA-responsive
2- hybrid reporter strain together with B42-E6AP_UB
(E6AP_UB fused to the B42 transactivation domain).
Interaction between lexA-16E6 and B42-E6AP_UB was
selected by 2-hybrid interaction on minus histidine plates,
and the lexA-16E6 plasmids selectively recovered from
pooled yeast colonies into bacteria by chloramphenicol re-
sistance. The plasmids were then introduced into yeast con-
taining a lexA responsive lacZ reporter and mated either to
a strain containing p53 and E6AP_UB or to yeast con-
taining B42 fused to E6AP_UB. Diploid yeast were
screened for blue color upon interaction with B42-
E6AP_UB, and pale blue or white color in yeast express-
ing E6AP_UB and p53 (Fig. 3C). Figure 3C shows a plate
from the secondary screen containing presumptively mutant
lexA-16E6 fusions meeting the selection criteria. The lexA-
16E6 plasmids were recovered and the 16E6 portion se-
Fig. 3. Analysis of p53, E6AP, and 16E6 interactions in yeast. (A) E6AP and 16E6 recruit p53 to form a trihybrid in yeast. TAT7 yeast containing an
integrated lexA responsive lacZ reporter were transfected with the indicated plasmids and empty vector plasmid so that each yeast strain contained three
plasmids (empty plasmids not indicated in the figure). After selection for HIS/LEU/URA prototrophs on glucose plates plus adenine and histidine, yeast were
patched onto galactose plates containing XGAL, histidine and adenine and scanned 2 days later. (B) Expression of p53, E6AP, and 16E6 fusions in yeast.
At the bottom of the figure, the expression of p53, E6AP or E6AP mutated in the ubiquitin ligase cysteine site (E6AP_Ub) are indicated for each lane. In
the top panel pair, lexA is expressed in each lane. In the middle panel pair, lexA-16E6 is expressed and in the bottom pair, unfused native 16E6 is expressed.
Detecting antibodies for western blots are indicated on the right: E6AP was detected using rabbit polyclonal antibody to E6AP. E6AP expression was lost
upon the co-expression of either native or lexA fused 16E6, but similar loss of p53 expression was not detected. (C) Secondary screen for 16E6 mutants that
interact with E6AP_Ub yet fail to interact with p53 in the presence of E6AP_Ub. Plasmids expressing lexA, lexA-16E6 and lexA-16E6 mutants selected
for interaction with B42_E6AP_Ub by 2-hybrid selection, and failure to form a transactivating trihybrid of lexA-16E6  E6AP_Ub  p53 were
introduced into TAT7 yeast containing an integrated lexA responsive lacZ reporter. Duplicate patches of the resulting strains were mated to yeast containing
either a transactivator fused E6AP_Ub (B42-E6AP_Ub) or unfused E6AP_Ub  p53. Mated and selected yeast were spotted onto Galactose/XGAL
indicator plates and scanned 3 days later. M1, M2, M3, etc refer to individual tested isolates. (D) Yeast selected mutants of 16E6 occur within conserved
residues in the amino-terminus of 16E6. Shown are the aligned amino-terminal sequences of HPV-31 E6, 18E6, and 16E6, and below that the same region
of HPV-11 and HPV-6 E6. Conserved residues among types 16, 18, and 33 are in bold font, and similar or conserved residues between both groups of E6
proteins are underlined. Above the E6 sequence alignments are the identities and locations of 16E6 mutations selected for interaction with E6AP_UB and
failure to form a trihybrid with p53. Two different independent mutations were recovered at the F2 position.
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quenced. Most of the yeast-selected 16E6 mutations af-
fected conserved amino acids in the amino-terminus of
16E6, prior to the beginning of sequence homology with E6
proteins that do not degrade p53 (Fig 3D). This corresponds
to a previously described mutation in 16E6 (16E6F2V)
which was shown to interact with E6AP yet not degrade p53
(Liu et al., 1999). Table 1 lists the identity and phenotypes
(discussed below) of the recovered mutants, and the iden-
tities and phenotypes of additional mutants created by site
directed mutagenesis.
Most of the mutations within the amino terminus of 16E6
were consistent with the expected outcome of the screen, in
that they interacted with E6AP in vitro and in yeast, failed
to interact with p53 in yeast, failed to recruit p53 to E6AP
in vitro, and had reduced or absent degradation of p53 in
vitro (Fig. 4 and Table 1). However, one recovered mutant,
E75G/K115E, was unexpected. The E75G/K115E mutation
failed to form a complex with p53 in yeast but in the
secondary screen in yeast had associated with E6AP_Ub.
This was the expected phenotype from the yeast screen, yet
the E75G/ K115E mutant failed to associate with E6AP in
vitro. This prompted us to re-examine the interaction of
16E6 with E6AP in yeast.
A point mutation was constructed in the E6 binding
motif of E6AP (amino acids 407–418), mutating the wild-
type LQELL sequence to LQELS (L413S mutation). This
mutation should abrogate the interaction of 16E6 and BE6
with the LQELL motif. Both the LQELL and LQELS iso-
lated binding motifs were cloned as fusions to GST and
tested for in vitro interaction with in vitro translated 16E6.
Figure 5A demonstrates that as expected the LQELS bind-
ing motif failed to interact with 16E6. The same results were
obtained with GST fused to the full length E6AP or to E6AP
containing the LQELS mutation as with the isolated motifs
shown in Fig. 5A (data not shown). In the converse bind-
ing reaction using GST-16E6 and in vitro translated
E6AP_Ub or E6AP_Ub LQELS, most but not all bind-
ing activity was eliminated upon mutation of the LQELL
motif to LQELS, with 3% specific binding remaining com-
pared to wild-type (data not shown). The binding of 16E6 to
Table 1
Amino-terminal and yeast selected 16E6 phenotypes
16E6
mutationa
E6AP binding LQELL
binding
p53 binding p53 degradation
Yeastb In Vitroc Yeastb Yeastb In Vitroc In Vitroc SAOS2 NIKSd
Wild type        
F2V        
F2E    ND   ND ND
F2K    ND   ND ND
F2G    ND    ND
F2L        ND
F2P    ND    ND
D4G    /    ND
P5R       ND ND
Q6A    /   ND ND
E7A        ND
R8Q        
K11E       / 
L12S        ND
P13L        ND
C16R  /      ND
C16S        ND
123V    /    ND
152T        ND
E75G/K115E        ND
Y79N    ND ND   
C103R    ND ND   ND
C111R      / / ND
F125L    ND ND   
a Mutations selected in yeast for association with E6AP_Ub and failure to associate, with p53 in a trihybrid are in bold font. Site directed mutations are
in normal font and mutations selected for association with E6AP_Ub and failure to associate with the isolated LQELL motif in yeast are underlined.
b Interaction of E6AP_Ub with lexA-16E6 and 16E6 mutants was assessed by liquid beta-galactosidase assay in microtiter plates as described (Ned et
al., 1997), normalized to wild-type E6.  represents 50–100% of activity,  represents 25–50% activity,  represents 10–25% and 0–10%.
/ refers to inconsistent activity between assays, with at least 1 assay greater than 0.
c In vitro binding assays performed as described in the methods using in vitro-translated 35S labeled E6 and bacterially expressed and purified GST-E6AP
Binding by the zinc finger mutant C103R was used as a negative control for non-specific interaction. Bound counts were quantitated by beta-counting of the
gel and normalized to binding by 16E6.  represents 50–100% of activity,  represents 25–50% activity,  represents 10–25% and 0–10%
refers to inconsistent activity between assays, with at least 1 assay greater than 0.
d NIKS degradation of p53 is a non-quantitative representation from Fig. 7D, included only for comparison purposes.
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the isolated LQELL motif is consistent with other mutagen-
esis studies of this motif and mutagenesis of BE6 binding
motifs that showed elimination of binding to motifs con-
taining non-conservative leucine mutations (Be et al., 2001;
Bohl et al., 2000). To test in vivo interaction of 16E6 with
the binding motif, we cloned the LQELL and LQELS pep-
tide motifs as fusions to the B42 transactivator, and we
incorporated the LQELS mutation into the full-length B42-
tagged E6AP and E6AP_Ub. Interaction of these “prey”
molecules in yeast was tested with lexA fusions to E6 in
yeast 2-hybrid interaction. Fig. 5B demonstrates that as
expected, the LQELL peptide interacts with both BE6 and
16E6, while the LQELS peptide does not. Full length E6AP
interacts weakly with only BE6, but a stronger interaction is
revealed upon mutation of the ubiquitin ligase activity of
E6AP (E6AP_Ub), and as expected when LQELL is mu-
tated to LQELS in the context of E6AP_Ub, the interac-
tion of BE6 with E6AP_Ub is lost. This is consistent with
BE6 interacting with E6AP only at the LQELL binding site.
Like BE6, 16E6 fails to interact with LQELS peptide, but
interacts with both LQELL and E6AP_Ub. However, un-
like BE6, 16E6 interacts strongly with E6AP_Ub LQELS,
where the E6 binding motif has been mutated. This indicates
that an additional direct or indirect interaction site or sites
exist on E6AP for 16E6. The E6 protein from European elk
papillomavirus (EEPV) was used as a non-specific negative
control, and failed to interact with any of the prey mole-
cules, indicating that none of the prey interactions were
non-specific for all E6 types.
In order to determine the role of the LQELL binding site
of E6AP in forming a tri-hybrid in yeast, we co-expressed
lexA fusions to E6AP and E6AP mutants with unfused
16E6, 16E6 mutants, and p53. Figure 5C demonstrates that
a trihybrid can be formed with lexA-E6AP_Ub 16E6
p53 (Fig. 3 used a lexA-16E6 fusion to recruit transactiva-
tion to the lexA responsive lacZ reporter). Efficient trihybrid
formation required a full length E6 molecule, as 16E6
1–116 formed a very weak trihybrid. An intact amino-
terminus of E6 was also required as 16E6 F2V and K11E
only weakly recruited transactivation in the presence of p53.
Neither 16E6 nor 16E6 mutants transactivated in the ab-
sence of p53. As in Fig. 3, mutation of the ubiquitin ligase
activity of E6AP was required for trihybrid interaction,
despite the presence of E6AP (demonstrated by the interac-
tion of B42-tagged BE6 with both E6AP and E6AP_Ub).
Surprisingly, an intact LQELL binding site on E6AP_Ub
was not required for strong trihybrid formation with 16E6
p53; indeed, trihybrid formation appeared more robust upon
mutation of LQELL to LQELS (Fig. 5C).
In order to determine the role of E6AP and the role of the
LQELL binding site of E6AP, we transfected E6AP-null
immortalized mouse embryo fibroblasts with targeted dele-
tions of both UBE3A (E6AP) alleles (Jiang et al., 1998)
with human p53, 16E6, E6AP or E6AP, mutants as indi-
cated in Fig. 6. Co-transfected p53 was detected with a
human p53 specific antibody that does not detect mouse
p53. Fig. 6 demonstrates that E6AP is required for the 16E6
dependent degradation of p53, and as had previously been
shown, ubiquitin ligase activity is required. However, an
intact LQELL motif was not required for the 16E6 depen-
Fig. 4. 16E6 mutants selected for non-interaction with p53 in yeast fail to degrade p53 in vitro. p53, 16E6, and the indicated 16E6 mutants were in vitro
translated in rabbit reticulocyte lysate and tested for association with bacterially expressed GST-E6AP fusion protein immobilized on beads (E6AP bound
E6), for the ability to recruit p53 to GST-E6AP (E6AP bound p53) and for the ability to degrade p53 in vitro (p53 in vitro degradation assay) over a 2 h
time period. The stability of 16E6 and 16E6 mutants during the p53 degradation assay is shown in the bottom 2 panels (E6 in vitro degradation assay).
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dent degradation of p53, indicating that strong interactions
between 16E6 and E6AP at this site are not essential. The
decreased expression of p53 in Fig. 6 in lanes 3 and 4 was
not consistently observed between experiments and is not
comparable to the decrease upon expression of E6. It is
possible that the LQELL site of E6AP recruits 16E6 to
E6AP allowing activity at low expression levels of E6, but
is not required for the degradation function of E6AP. To test
this possibility, we performed a titration of 16E6 together
with p53 and E6AP or E6AP_LQELS. Similar amounts of
16E6 were required for the degradation of p53 with either
E6AP or E6AP_LQELS (Fig 6B).
In order to further determine the role of LQELL-depen-
dent and LQELL- independent interactions between 16E6
and E6AP, we performed an additional yeast screen for
16E6 mutants that interacted strongly with E6AP_Ub,
failed to interact with the LQELL peptide, yet formed a
trihybrid when co-expressed with E6AP_Ub  p53 in
yeast. Mutagenized lexA-16E6 fusions were selected for
interaction with B42-fused E6AP_Ub prey molecules in a
Fig. 5. Mutation of the E6 binding motif of E6AP abrogates interaction of BE6 with E6AP but fails to abrogate interaction of 16E6 with E6AP in yeast. (A)
Mutation of the E6 binding motif abrogates 16E6 binding in vitro. Bacterially expressed and immobilized GST and GST fused to the 16E6 binding motif
of E6AP (amino acids 407–418, LQELL) or mutated 16E6 binding motif (amino acids 407–418, LQELS) were incubated in vitro with 35S labelled in vitro
translated 16E6. 10% of the binding reaction for GST prior to the washing of the beads was loaded in the far right lane. 16E6 binds LQELL but not LQELS
peptide in vitro. (B) 16E6 interacts with both the LQELL peptide of E6AP and another site(s) of E6AP in yeast. LexA fusions to the indicated E6 proteins
were expressed in horizontal rows and mated to strains in vertical columns expressing B42 transactivator fusions to the isolated E6AP E6 binding motif
(amino acids 407–418, LQELL)), mutated peptide from E6AP (amino acids 407– 418, LQELS), full length E6AP, E6AP mutated in the ubiquitin ligase
thioester site (E6AP_Ub), or E6AP mutated in both the ubiquitin thioester site and the E6 binding motif (E6AP_Ub, LQELS). Mated yeast were selected
and patched onto XGAL indicator plates for the transactivation of a lexA-responsive lacZ reporter. EEPV refers to European Elk Papilloma virus E6, and
16E6_1–116 to a nonsense mutation in 16E6 at codon 117. (C) Formation of a trihybrid complex consisting of p53, E6AP, and 16E6 in yeast does not require
an intact LQELL E6 binding motif on E6AP. Yeast strains expressing lexA fusions to E6AP, E6AP mutated in the ubiquitin thioester site (E6AP_Ub) or
E6AP mutated in both the ubiquitin thioester and 16E6-binding sites (E6AP_Ub, LQELS) were mated to strains in vertical columns expressing the indicated
genes. p53, 16E6, and 16E6 mutants are unfused proteins, while in the right panel transactivator fusion vector expressing B42 or B42 fused to BE6 are
expressed (p53 in the right panel is native). Not shown are empty vector plasmids co-expressed so that all mated strains are equivalent for auxotrophic
markers. Mated yeast were expanded on selective plates and patched onto XGAL indicator plates to assay a lexA responsive lacZ reporter. p53 is recruited
by 16E6 to E6AP mutated in the canonical LQELL 16E6-binding motif.
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standard two-hybrid reaction, the lexA-16E6 bait plasmids
recovered into bacteria on chloramphenicol plates, and the
pool of recovered mutants were then introduced into TAT7
yeast containing a B42_LQELL peptide prey molecule.
White colonies were picked, lexA-16E6 plasmids recovered
and then screened for the ability to form a trihybrid with
p53, the ability to interact with the B42-tagged LQELL
peptide, and the ability to interact with E6AP_Ub prey in
yeast as illustrated in Fig. 7A. DNA sequencing of lexA-
16E6 recovered from this screen revealed several duplicate
isolates falling into three mutations. 16E6 Y79N, 16E6
F125L, and 16E6 F125L/R144G. The Y79N and F125L
mutants were further analyzed.
Fig. 7A demonstrates that both lexA-16E6 Y79N and
lexA-16E6 F125L interacted strongly with B42 fusions to
E6AP_Ub and E6AP_Ub LQELS yet failed to interact
with the isolated B42-LQELL or LQELS prey molecules.
Figure 7B shows that neither the unfused in vitro translated
Y79N or F125L 16E6 mutants could bind to the LQELL
motif in vitro. Fig. 7B illustrates that like the amino-termi-
nal 16E6 mutant F2V, 16E6 Y79N was defective for in vitro
degradation of p53. However, 16E6 F125L was almost
equal to wild-type 16E6 for degradation of p53 in vitro,
even though it failed to interact with the LQELL motif.
Similar results for the degradation of p53 were obtained for
in vivo degradation of transfected p53 in Saos2 cells. Saos2
cells are null for p53 and 16E6, but express E6AP. Trans-
fected wild-type 16E6 and 16E6 F125L decreased p53 ex-
pression while 16E6 F2V and 16E6 Y79N did not (Fig. 7C).
Because of the uncertainties of overexpression systems,
we wished to determine if 16E6 F125L would be competent
to decrease p53 expression in relevant cells stably express-
ing E6. Normal human immortalized keratinocytes (NIKS
cells) express wild- type p53, and support the complete life
cycle replication of HPV-16 in organotypic cultures (Flores
et al., 1999). In comparison to primary keratinocytes, NIKS
cells are suited for the observation of some E6 phenotypes
since the use of an immortalized cell avoids making com-
parisons between less slowly growing cells and actively
growing cells (as occurs with comparisons of primary ker-
atinocytes to keratinocytes that express 16E6). NIKS cells
were retrovirally transduced with empty vector, E6, and E6
mutants. Early passage drug-selected cells were tested for
the induction of human p53 by mitomycin C treatment.
Vector transduced NIKS cells strongly induce p53 upon
mitomycin C treatment, while cells expressing wild-type, or
carboxy-terminal deletion mutant of the last 2 amino acids
(disrupting the PDZ-domain binding motif of 16E6) pre-
vented induction of detectable p53 (Fig. 7D). NIKS cells
expressing 16E6 F125L that is defective for binding the
LQELL motif, expressed undetectable p53 basally and were
defective for the induction of p53 by mitomycin C, and
therefore in this regard similar to cells transduced with
wild-type 16E6. NIKS cells expressing 16E6 mutants de-
fective for degradation of p53 in vitro (R8Q, K11E, and
Y79N) all increased p53 protein upon mitomycin C treat-
ment, but less than the increase observed in NIKS cells not
expressing E6. Interestingly, NIKS cells transduced with E6
genes defective for in vitro degradation of p53 (BE6, R8Q,
K11E, Y79N) had elevated levels of p53 in the untreated
cells compared to vector transduced NIKS cells; however
all these cells increased p53 levels upon mitomycin C treat-
ment, albeit at attenuated levels compared to vector trans-
duced NIKS cells (Fig. 7D).
Discussion
E6 proteins have conserved overall structure yet have
diverse biological functions and distinctly different associ-
ations with cellular proteins. The best-studied E6 proteins
are from the cancer-associated human papillomaviruses,
HPV-16 and 18, and BPV-1 E6. Both of these E6 types
interact with target cellular proteins through binding to
LXXLL peptides. In the case of BE6, binding to paxillin
through LXXLL interactions correlates closely with trans-
formation of murine C127 cells, although transformation
requires an additional function beyond simple association
with paxillin (Das et al., 2000); that additional function may
be an adapter function as has been proposed for 16E6 in the
degradation of p53. How E6 proteins act as adapter mole-
cules has been suggested by the analysis of site directed
mutations of 16E6 targeting the degradation of p53, where
mutations at the amino-terminus of 16E6 have been found
to be defective for the degradation of p53 (Gewin and
Fig. 6. Requirement of E6AP for degradation of p53 in vivo. (A) E6AP is
required for the degradation of p53 by 16E6 in vivo. Human p53, 16E6,
E6AP or the indicated E6AP mutants (as described in Fig. 5) were co-
expressed as indicated into mouse fibroblasts null for E6AP. Transfected
human p53 was detected with human- specific p53 monoclonal antibody.
While E6AP is necessary for p53 degradation, E6AP mutated in the
canonical E6 binding motif supports p53 degradation. (B) E6AP_LQELS
supports degradation of p53 in vivo. P53 and the indicated amounts (ng.) of
16E6 were co-expressed together with E6AP or E6AP_LQELS in mouse
fibroblasts null for E6AP. Empty plasmid vector was used to equalize the
total transfected plasmid in each lane. E6AP and E6AP_LQELS require
similar amounts of 16E6 to degrade p53.
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Galloway, 2001; Liu et al., 1999), to influence the interac-
tion with E6AP (Gewin and Galloway, 2001), and further as
in our study, been found to bind and catalyze the degrada-
tion of E6AP, yet fail to target the degradation of p53 (Kao
et al., 2000).
In order to further investigate the adapter function of
16E6, a three-way complex (trihybrid) of 16E6, p53, and
E6AP was formed in yeast. The transactivation observed by
the trihybrid is presumed to be due to the transactivation
function of p53, although this is not proven, and could be
due to a novel function of E6 or E6AP revealed upon
trihybrid formation with p53. A prior study that examined
the interaction of 16E6 with p53 showed substantial direct
interaction of p53 with gal4:16E6 fusions; however in that
study a transactivator fusion to p53 was the interacting
partner while in our study native p53 was used (Elbel et al.,
1997). In our study, direct interaction of p53 with lexA-
16E6 in yeast was not consistently observed; it is possible
that such an interaction, if it occurs, does not expose a
transactivation function. In our study, the trihybrid was used
to screen for 16E6 mutations that lost interaction with p53
and retained interaction with E6AP. Most of these muta-
tions were localized to the amino terminus prior to the first
zinc finger of 16E6 (amino acids 2–23). This correlates well
with the failure of amino-terminal deletion mutants of 16E6
to degrade p53. All E6 amino-terminal mutants that were
able to recruit p53 to E6AP in vitro were also able to
degrade p53 in vitro (Fig. 4), and mutants that failed to
recruit p53 to E6AP in vitro all failed to degrade p53 in
vitro. The same was not found upon comparing in vitro
binding with in vivo p53 degradation. In vitro binding dem-
onstrated that deletion of 16E6 from amino acid 8 to 13
Fig. 7. 16E6 F125L mutant fails to bind the LQELL motif of E6AP yet decreases p53 expression in vitro and in vivo. (A) 16E6 mutants Y79N and F125L
fail to interact with the LQELL motif, yet retain interaction with E6AP_Ub in yeast. LexA or the indicated lexA fusions were expressed in the YSV90 lexA
reporter strain in horizontal rows and mated to YPH499 strains expressing B42 transactivator or the indicated B42 fusions to the LQELL peptide, mutated
LQELS peptide, E6AP, or the indicated E6AP mutants. Mated yeast was selected and equal amounts spotted onto galactose/XGAL plates plus leucine. Plates
were scanned after 24 h incubation (B) 16E6 F125L fails to bind the LQELL motif of E6AP in vitro yet degrades p53 in vitro. in vitro translated wild-type
16E6 (WT) or the indicated 16E6 mutants were in vitro translated and tested for in vitro binding to GST fused to the E6AP LQELL peptide in the upper
panel pair. Neither 16E6 Y79N nor 16E6 F125L bind to LQELL in vitro. In the bottom panel, 16E6 or the indicated mutants were tested for in vitro
degradation of 35-S labeled p53 in a 60-minute reaction. Mock refers to a water-programmed in vitro translation reaction, used as a minus E6 control. 16E6
F125L substantially degrades p53 while 16E6 Y79N does not. (C) 16E6 F125L decreases p53 expression in transient transfections of SAOS2 cells. p53 and
the indicated amounts in nanograms of 16E6 or 16E6_F125Lmolecule were co-transfected into SAOS2 cells as described in Methods. P53 expression was
determined by western blot of whole cell lysates with p53 specific monoclonal antibody. (D) 16E6 F125L decreases p53 expression in stably transduced
keratinocytes. Normal immortalized keratinocytes (NIKS cells) were retrovirally transduced with empty vector, BPV-1 E6 (BE6), 16E6, or the indicated 16E6
mutants and selected for puromycin drug resistance. Equal numbers of early passage (passage 4–8) cells after drug selection were mock treated, or were
treated with 10-g/ml mitomycin C for 4 or 8 h before lysis in SDS-PAGE sample buffer. Shown are western blots for p53 expression using a human specific
monoclonal antibody for p53.
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resulted in a substantial decline of in vitro association with
E6AP (Fig. 2A), indicating that the amino-terminus of 16E6
is required for both the adapter function of p53 interaction
as well as the E6AP_LQELL binding function of 16E6. The
yeast selected mutant 16E6 I23V is also in the amino ter-
minal region required for p53 association and in vitro E6AP
binding, indicating that the amino terminus has overlapping
specificity for both p53 and E6AP. However, the in vivo
overexpression analysis demonstrated less stringent require-
ments for both p53 degradation as well as E6AP degrada-
tion. Surprisingly, upon overexpression, 16E6 amino acids
1–8 were dispensable for p53 degradation, and further de-
letion to amino acid 13 resulted in the loss of p53 degrada-
tion but the retention of E6AP degradation. This indicates
that a core requirement for p53 degradation exists between
amino acids 8–13 and that amino acids 1–8 are an acces-
sory function that appears as a complete requirement during
in vitro degradation assays (Fig. 7B) and during stable in
vivo expression assays (Fig. 7D). Interestingly, yeast-se-
lected mutants K11E, L12S, and P13L are within this core
region. 16E6 could be deleted to amino acid 22, and al-
though E6 expression levels progressively declined, E6AP
expression was abrogated, similar to wild-type 16E6. That
16E6 molecules deleted to amino acid 13 failed to interact
efficiently with E6AP in vitro (Fig. 2A), yet degraded E6AP
in vivo (Fig. 2B), called into question the assay and inter-
pretation of the strong in vitro association of E6 with E6AP.
The strong in vitro binding site of E6AP for 16E6 has been
previously demonstrated to be the LQELL motif.
BE6 interaction with E6AP in vitro and in yeast was
consistent with interaction only at the LQELL motif of
E6AP (Figs. 5B and C). However, 16E6 interactions in
yeast were also consistent with an additional mechanism for
interaction of 16E6 with E6AP (Fig. 5B). In order to deter-
mine the role of strong association between 16E6 and E6AP
at the LQELL site, we analyzed two mutants for interactions
with E6AP and the ability to support p53 degradation. A
mutation in the isolated LQELL motif to LQELS lost inter-
action with 16E6 in vitro and in yeast while the
E6AP_LQELS mutant retained interaction with 16E6 in
yeast, formed a trihybrid in yeast, and supported p53 deg-
radation in E6AP null cells (Fig. 5). It is possible that while
interaction of 16E6 with the isolated LQELL motif was
abrogated upon mutation to LQELS, some residual signifi-
cant interaction of 16E6 with LQELS remains in the context
of the full length E6AP. Alternatively, a second mode of
interaction between 16E6 and E6AP may account for deg-
radation supported by the E6AP_LQELS mutant. At the
very least, the interaction of 16E6 with E6AP at the LQELL
motif in vitro does not correlate with either the ability to
form a trihybrid in yeast or to degrade p53. To further
support this analysis, we selected a mutant of 16E6 that lost
the ability to interact with the LQELL motif. This mutant,
16E6 F125L, was able to induce p53 degradation in vitro, in
vivo in SAOS2 cells, and in keratinocytes stably expressing
16E6 F125L. While some residual interaction of 16E6
F125L with E6AP may remain undetected in these experi-
ments, this mutant indicates that strong interactions with
this motif, as observed with wild-type 16E6, are not re-
quired for the degradation of p53. A deletion mutant of
E6AP that deleted 18 amino acids encompassing the
LEQLL motif fails to support p53 degradation in vitro or in
vivo (Huibregtse et al., 1993b). While such a deletion re-
moves the possibility of a residual E6 interaction, it is
possible this deletion also alters some other functional fea-
ture of E6AP.
Using E6AP-null fibroblasts, we demonstrated that
E6AP is both necessary and sufficient for 16E6 to degrade
p53. But how a complex of p53, 16E6, and E6AP is assem-
bled and how degradation is triggered remains unclear. The
simplest model is that 16E6 interacts with E6AP at the
LQELL motif through interactions with both zinc fingers (as
found with BE6), recruits p53 in part through contacts with
the amino-terminus of 16E6, and that this interaction dis-
torts the structure of E6AP, triggering ubiquitin ligase ac-
tivity. It is noteworthy that BE6 also interacts with E6AP at
the LQELL site yet unlike 16E6 it failed to initiate either
p53 or E6AP degradation upon overexpression in mamma-
lian cells (Fig. 1) or in yeast (B. Cooper and S.B. Vande Pol,
unpublished observations). This indicates that a separate
function of 16E6, independent from interaction with the
LQELL motif of E6AP, is required for triggering the ubiq-
uitin ligase activity of E6AP. The results discussed above
raise the possibility that this triggering function may be
interaction of 16E6 with a separate site or interaction by a
different mechanism with E6AP.
Examination of Fig. 5C shows that 16E6 molecules with
amino-terminal mutations are greatly reduced for formation
of a trihybrid with p53, but that some residual transactiva-
tion remains. Similar results were found with mutant 16E6
I52T (not shown in Fig. 5). The possibility remains that the
first zinc finger of 16E6 has some contacts with p53 inde-
pendent of the amino terminus. We are currently screening
for mutants of 16E6F2V that eliminate this residual trihy-
brid formation yet retain E6AP association to address this
possibility.
The results in this study also have implications for as-
sessing the role of E6AP in non-p53 dependent processes.
E6 mutants that either interact or fail to interact with E6AP
in vitro have been used to determine if E6AP is involved in
an E6 dependent process such as degradation of the GAP
protein E6TP1 (Gao et al., 2001), activation of telomerase
activity (Gewin and Galloway, 2001), or degradation of
PDZ containing proteins that interact with the carboxyl-
terminus of E6 (Thomas et al., 2001). This study demon-
strates that an E6 mutant such as F125L can participate in an
E6AP dependent process (p53 degradation) yet fail to in-
teract with E6AP in an in vitro binding assay. It would
appear that only E6AP null cells are an appropriate exper-
imental system for determining the role of E6AP in an
E6-dependent process.
The induction of p53 levels in NIKS cells transduced by
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E6 molecules defective for p53 degradation is intriguing, in
that it implies that HPV-16E6 proteins may induce p53 by
an unknown mechanism, and then target that p53 for deg-
radation. While the induction of p53 by E7 proteins has
been noted in many DNA tumor virus systems, the mech-
anism of induction by E6 proteins has not been investigated.
Alternatively, it is possible that there is a selection for the
expansion of rare NIKS cells containing mutant p53 upon
infection with 16E6 mutants defective for degradation of
p53. The transcriptional properties and possible mutation of
the “induced” p53 in these NIKS cells is under investiga-
tion.
The interaction of both BE6 and 16E6 with similar
LQELL motifs has raised the possibility that drugs could be
devised that would significantly reduce this interaction.
Such drugs might block 16E6-induced p53 degradation and
thereby restore p53 function in cervical cancers with a
resulting therapeutic benefit. Indeed, the competitive block
of BE6 transformation by LXXLL motifs has provided
support for this concept (Bohl et al., 2000). However, the
results of the current study show that 16E6 mutants that
interact very weakly if at all with the LQELL motif of E6AP
(F125L) and E6AP mutated in the LQELL motif
(E6AP_LQELS) can support p53 degradation. If weak re-
sidual interaction of E6 F125L with the LQELL motif were
responsible for this activity, then drug-mediated reduction
of wild type 16E6 interaction with LQELL below this level
of interaction could be difficult to achieve. A recent study
using overexpressed peptide aptamers in cervical cancer
cells showed induction of apoptosis upon expression of a
subset of aptamers that interacted with 16E6, however the
relationship of those aptamer sequences to the LQELL mo-
tif and or p53 is as yet undetermined (Butz et al., 2000).
Materials and methods
Cells and tissue culture
CV-1 and SAOS2 cells were maintained in DMEM me-
dia supplemented with 10% newborn calf serum, glutamine
and antibiotics. NIKS cells are normal immortalized human
keratinocytes that are passaged on 3T3 feeder cells as de-
scribed (Allen-Hoffmann et al., 2000). E6AP null mouse
fibroblasts are derived from primary mouse embryo fibro-
blasts deleted in both Ube3a genes and are spontaneously
immortalized (Jiang et al., 1998). Mammalian cells were
transfected by FUGENE-6 in accordance with the manufac-
turer’s instructions, and transient Vaccinia virus expression
of proteins was performed in CV-1 cells as described (El-
roy-Stein et al., 1989).
Plasmids
Glutathione-S transferase (GST) fusions to E6AP have
been previously described (Vande Pol et al., 1998). For
expression of native E6 molecules, yeast CUP1 promoter
expression plasmids with 2-micron origins and Ade2 or
URA3 selection were created. A 419 nt fragment of the
CUP1 promoter (corresponding to nucleotides 1112 to 1531
the CUP1 gene, Genbank accession K02204) was PCR-
amplified using the plasmid p426HSE-M as template (Ta-
mai et al., 1994), generously provided by Dr. Dennis
Thiele), in which the heat shock element is mutated and a
XbaI site 130 nt upstream of the transcription start site has
been mutated. The 5 per oligo contains a unique SacI site
at the beginning of the CUP1 promoter, and the 3 oligo
contains NcoI and XmaI sites at the 3 end. The resultant
CUP1 PCR fragment was inserted together with the ADH
terminator (a 274 nt. XmaI to SphI fragment from pEG202
(Gyuris et al., 1993) into the yeast plasmid pASZ11 with
ADE2 selection. Similar CUP1 expression plasmids with
high copy 2-micron origins and URA3 selection were de-
rived by plasmid fragment exchange. LexA fusions were
expressed in yeast from the pLexA plasmid using the ADH
promoter on a 2-micron ori plasmid with URA3 and chlor-
amphenicol for yeast and bacterial selection respectively
(Das et al., 2000). Yeast prey plasmid pJG4-5 expresses
fusions to the B42 transcriptional activation domain under
control of the Gal1 promoter with TRP1 and ampicillin
selection (Gyuris et al., 1993). p53 was expressed from the
ADH promoter in the plasmid pYADE4 with TRP1 and
ampicillin selection (Brunelli and Pall, 1993). Unfused
E6AP or E6AP mutants were expressed from the ADH
promoter with LEU2 and ampicillin selection. For transient
expression of proteins in mammalian cells, 16E6 genes were
cloned into pcDNA3 (Invitrogen) and E6AP genes into
pCMV-FLAG. Human p53 expression plasmid p53SN was
used for transient expression of human p53. For retroviral
transfection of mammalian cells, 16E6 genes were cloned
into pBabe-puro (Morgenstern and Land, 1990) and retro-
virus packaged by transient transfection of Pheonix Ampho
cells (generously provided by Gary Nolan, Stanford Uni-
versity). Human E6AP and E6AP_Ub cDNA’s were pro-
vided by John Huibregtse (University of Texas, Austin) and
are numbered in accordance to Genbank Q05086.
Yeast expression. The TAT7 strain of yeast was a gift of R.
Sternglanz and contains lexA responsive lacZ and His3
reporter genes, and is MATa, leu2, ade2, and trpl. YSV90
is the yeast 2-hybrid reporter strain EGY48 (MAT-alpha,
his3, trp1, ura3–52, leu2::pLEU2-lexAop6) (Gyuris et al.,
1993) containing a lexA responsive lacZ reporter plas-
mid with HIS3 selection. YPH 500 and YPH499 are mat a
and alpha respectively and are ura 3–52, ly2–801, ade2–
101, trp1–63, his3–200, leu21 and are used to intro-
duce plasmids by mating into TAT7 or YSV90 strains by
yeast mating. Empty expression plasmids containing appro-
priate selection markers were introduced into mating strains
so that for any particular experiment all selected yeast
contained the same number of plasmid types and expressed
the same auxotrophic phenotypes. Yeast mating, selection
and transfection were as previously described (Vande Pol et
al., 1998).
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Yeast mutagenesis experiments. 16E6 was mutagenized in
the pLexA plasmid by gap repair mutagenesis (Muhlrad et
al., 1992). A 0.8 kb fragment from pLexA-16E6 was PCR
amplified using primers located within lexA upstream of the
EcoRI site at the start of 16E6 sequences, and within the
ADH1 transcriptional terminator 232 nt 3 of the XhoI clon-
ing site. Manganese was added to the per reaction to reduce
the bias for transitional mutations and to increase the mu-
tation frequency. In order to screen for E6 mutants that
retain association with E6AP yet fail to interact with p53,
gap-repair mutagenesis of 16E6 was performed in TAT7
yeast containing B42 transactivator fused to E6AP_Ub
(E6AP_Ub prey). Interaction between 16E6 and E6AP
was selected by 2 cycles of growth on minus histidine plates
plus 20 mM 3-amino-triazole. 16E6-expressing plasmids
were recovered by electroporation of yeast mini-prep plas-
mid DNA into bacteria and selection on plates containing
chloramphenicol. The recovered plasmid DNA from pooled
bacterial colonies was transfected into TAT7 yeast express-
ing unfused E6AP_Ub and p53. White or pale blue col-
onies were expanded and plasmid DNA recovered into
bacteria plated on chloramphenicol containing media.
TAT7 yeast were transfected with the pooled recovered
plasmids and individual yeast colonies picked and mated to
YPH500 yeast expressing either B42-E6AP_Ub prey fu-
sion and a empty LEU2 plasmid, or to YPH500 yeast
expressing p53 and unfused E6AP_Ub. Mated yeast were
screened for transactivation of a lexA responsive lacZ re-
porter in the presence of B42-E6AP_Ub and pale blue or
white transactivation in the presence of p53 and unfused
E6AP_Ub. Individual yeast colonies were expanded and
lexA-16E6 expressing plasmids recovered into bacteria se-
lected on chloramphenicol plates.
In vitro translation and in vitro-binding assays. In vitro
binding assays utilizing in vitro transcribed and translated
proteins were performed as previously described (Vande
Pol et al., 1998). In vitro p53 degradation assays were
performed essentially as described (Huibregtse et al.,
1993b). For in vitro binding assays 0.1 g of GST fusion
protein immobilized on glutathione agarose beads was re-
suspended in 150 l 0.5 binding buffer (1 binding
buffer contains 0.15 M NaCl; 50 mM Tris pH 7.4, 1%
NP-40, 1.0 mM DTT and 0.5 mM phenylmethylsulfonyl
floride) together with 5 l of in vitro translated and 35S
cysteine-labeled rabbit reticulocyte lysate programmed to
translate E6 or E6 mutants. The binding reaction was incu-
bated 4 h at 4°C prior to washing of the beads 3 times with
1.5 ml of binding buffer. E6 proteins were then resolved on
15% SDS PAGE protein gels, and visualized by autoradiog-
raphy.
Western blot analysis
Transfected mammalian cells or yeast were lysed in
SDS–PAGE sample buffer, proteins resolved by SDS–
PAGE electrophoresis and transferred to PVDF membranes.
Epitope tagged E6 and E6AP was detected with mouse
monoclonal antibody to the EE epitope (a gift of Gernot
Walter, University of California, Sam Diego). Mouse
monoclonal antibody Ab-8 that is specific for human p53
(Oncogene Science) was used to probe PVDF membranes
with peroxidase coupled secondary antibodies and demilu-
minescent detection.
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